先聲藥業(02096.HK)口服新冠藥納入醫保目錄 每盒藥品降至479元人幣
據《第一財經》報道,三款今年獲批上市的國產新冠藥均被正式納入醫保。此次進入醫保目錄後,價格有所調低。其中,先聲藥業(02096.HK)的口服新冠藥先諾欣(先諾特韋/利托那韋組合包裝)每盒/療程價格降至479元人民幣。君實生物(01877.HK)(688180.SH)的民得維(氫溴酸氘瑞米德韋片)及眾生藥業的樂睿靈(來瑞特韋片)尚未公布其新冠口服藥最新醫保定價。
醫保報銷的範圍均限輕中度新型冠狀病毒感染(COVID-19)的成年患者,醫保報銷日期從2024年1月1日至2025年12月31日。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.